Kintara Therapeutics Inc
Change company Symbol lookup
Select an option...
KTRA Kintara Therapeutics Inc
GLDI Credit Suisse X-Links Gold Shares Covered Call ETN
BILL Holdings Inc
AUB Atlantic Union Bankshares Corp
TSM Taiwan Semiconductor Manufacturing Co Ltd
STNG Scorpio Tankers Inc
FFIE Faraday Future Intelligent Electric Inc
SSBI Summit State Bank
ARGO Argo Group International Holdings Ltd
UWMC UWM Holdings Corp

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Blend
Company profile

Kintara Therapeutics, Inc. is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to available therapies, with particular focus on orphan cancer indications. The Company’s two lead candidates include VAL-083 and REM-001. Its VAL-083 is a novel, validated, deoxyribonucleic acid (DNA) targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG) The Company’s REM-001, a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC); basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients.

Closing Price
Day's Change
0.0375 (1.03%)
B/A Size
Day's High
Day's Low

10-day average volume:

Freeport-McMoRan Inc. Stock Falls Wednesday, Still Outperforms Market

4:53 pm ET August 31, 2022 (MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Freeport-McMoRan Inc. (FCX) slipped 0.54% to $29.60 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.78% to 3,955.00 and Dow Jones Industrial Average falling 0.88% to 31,510.43. This was the stock's fourth consecutive day of losses. Freeport-McMoRan Inc. closed $22.39 below its 52-week high ($51.99), which the company reached on March 25th.

Trading volume (19.6 M) remained 789,711 below its 50-day average volume of 20.4 M.

Data source: Dow Jones Market Data, FactSet. Data compiled August 31, 2022.


(END) Dow Jones Newswires

August 31, 2022 16:53 ET (20:53 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.